Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel

Cancer Biology and Therapy

Volumn 13, Issue 3, 2012, Pages 156-163

  Zhao, Weihong ^a,b   Song, Yongmei ^a   Xu, Binghe ^a   Zhan, Qimin ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast carcinoma; Chemotherapy; Drug resistance; Nlp; Paclitaxel; Target therapy; Tumorigenesis

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BETA TUBULIN; CARBOPLATIN; CELL PROTEIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; NINEIN LIKE PROTEIN; PACLITAXEL; POLO LIKE KINASE 1; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CELL SURVIVAL; CENTROSOME; CHEMOSENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROTUBULE ASSEMBLY; MULTIPLE CYCLE TREATMENT; POLYMERIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; MIDDLE AGED; NUCLEAR PROTEINS; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; UP-REGULATION; YOUNG ADULT;

EID: 84863178554     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.3.18697     Document Type: Article

References (45)

1. Vincent T. DeVita J SHS(Ed): CANCER:Principles and Practice of Oncology (ed 7th). Philadelphia, PA 19106 USA: LIPPINCOTT WILLIAMS & WILKINS.
2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-83; PMID:11033070; http://dx.doi. org/10.1016/S0928-0987(00)00114-7
3. Hatanaka H, Abe Y, Naruke M, Asai S, Miyachi H, Kawakami T, et al. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistanceassociated protein (MRP) ribozyme. Anticancer Res 2001; 21:879-85; PMID:11396179
4. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600; PMID:8770536; http://dx.doi.org/10. 3109/10409239509083491
5. Dingemans AC, van Ark-otte AJ, Span S, Scagliotti GV, der Valk PV, Postmus PE, et al. Topoisomerase II alpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32: 117-28; PMID:11325482; http://dx.doi.org/10.1016/ S0169-5002(00)00224-5
6. DiPaola RS, Aisner J. Overcoming bcl-2- and p53- mediated resistance in prostate cancer. Semin Oncol 1999; 26:112-6; PMID:10190792
7. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22:90-7; PMID:12527911; http://dx.doi.org/10. 1038/sj.onc.1206056
8. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell 1999; 91:451-60; PMID:10519005; http://dx.doi.org/10.1016/ S0248-4900(99)80086-0
9. Godinho SA, Kwon M, Pellman D. Centrosomes and cancer: how cancer cells divide with too many centrosomes. Cancer Metastasis Rev 2009; 28:85-98; PMID: 19156503; http://dx.doi.org/10.1007/s10555-008-9163-6
10. Lingle WL, Salisbury JL. The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol 2000; 49:313-29; PMID:11005025; http://dx.doi. org/10.1016/S0070-2153(99)49015-5
11. Kong Q. Cell brain abnormalities in cancer development. Med Hypotheses 2003; 61:120-5; PMID: 12781654; http://dx.doi.org/10.1016/S0306-9877(03) 00143-9
12. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002; 99:1978-83; PMID:11830638; http://dx.doi.org/10.1073/pnas. 032479999
13. Liu L, Zou P, Zhang M, Tian L, Liu F. Effect of pololike kinase 1 gene silence on cell cycle and drug resistance in K562/A02 cell. Chin Med J (Engl) 2006; 119:605-8; PMID:16620704
14. Ro S, Yang LX. Centrosomes-their role in tumors and cancer therapy. Anticancer Res 2004; 24:3269-73; PMID:15510622
15. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62; PMID:12559175; http:// dx.doi.org/10.1016/S1535- 6108(02)00235-0
16. Dutertre S, Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol Interv 2003; 3:127-30; PMID: 14993419; http://dx.doi.org/10.1124/mi.3.3.127
17. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominantnegative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11:615-23; PMID:11149596
18. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora- A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006; 119:2304-12; PMID:16894566; http://dx.doi.org/10.1002/ijc.22154
19. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7; PMID:14981513; http://dx.doi. org/10.1038/nm1003
20. Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res 2010; 70:6325-35; PMID: 20647325; http://dx.doi.org/10.1158/0008-5472.CAN-10-0015
21. Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26:5793-807; PMID:17369857; http://dx.doi.org/10. 1038/sj.onc.1210355
22. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines. Cancer Res 2010; 70:9846-54; PMID: 20935223; http://dx.doi.org/10.1158/0008- 5472.CAN-10-3001
23. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659-68; PMID:15547178; http://dx.doi.org/10.1093/jnci/ djh312
24. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repairmediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998; 58:1120-3; PMID:9515792
25. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22:2396-404; PMID:12717416; http://dx.doi.org/ 10.1038/sj.onc.1206319
26. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5:1001-7; PMID: 16639080; http://dx.doi.org/10.4161/cc.5.9.2726
27. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97:575-86; PMID: 10367887; http://dx.doi.org/10. 1016/S0092-8674(00) 80769-2
28. Wang Y, Zhan Q. Cell cycle-dependent expression of centrosomal ninein-like protein in human cells is regulated by the anaphase-promoting complex. J Biol Chem 2007; 282:17712-9; PMID:17403670; http:// dx.doi.org/10.1074/jbc.M701350200
29. Yu L, Song Y, Zhang Q, Zhan Q. Ninein-like protein is overexpressed in head and neck squamous cell carcinoma and contributes to cancer growth and resistance to apoptosis. Oncol Rep 2009; 22:789-98; PMID: 19724857
30. Qu D, Qu H, Fu M, Zhao X, Liu R, Sui L, et al. Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis. Gynecol Oncol 2008; 110:230-6; PMID:18538832; http://dx.doi.org/10.1016/j.ygyno.2008.04.015
31. Jin S, Gao H, Mazzacurati L, Wang Y, Fan W, Chen Q, et al. BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression. J Biol Chem 2009; 284:22970-7; PMID:19509300; http:// dx.doi.org/10.1074/jbc.M109.009134
32. Shao S, Liu R, Wang Y, Song Y, Zuo L, Xue L, et al. Centrosomal Nlp is an oncogenic protein that is geneamplified in human tumors and causes spontaneous tumorigenesis in transgenic mice. J Clin Invest 2010; 120:498-507; PMID:20093778; http://dx.doi.org/10. 1172/JCI39447
33. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008; 10:1268-74; PMID:18953436
34. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-8; PMID:14559807
35. Lentini L, Amato A, Schillaci T, Insalaco L, Di LA. Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells. Oncol Res 2008; 17:115-25; PMID:18669163
36. Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, et al. Down-regulation of Pololike kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66:5836-46; PMID:16740723; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-0343
37. Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable C. Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy. Mol Cancer Ther 2007; 6:1534-43; PMID:17513602; http://dx.doi.org/10.1158/1535-7163.MCT-06-0727
38. Song Y, Zhao C, Dong L, Fu M, Xue L, Huang Z, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis 2008; 29:307-15; PMID:18048386; http://dx.doi.org/10. 1093/carcin/bgm269
39. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5(Suppl 6):S3-6; PMID:7865431
40. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3:193-203; PMID:12769688; http://dx.doi.org/10.2174/1568009033481967
41. Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005; 4:1847-53; PMID:16294009; http://dx.doi.org/10.4161/cc.4.12.2264
42. Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007; 60:27-34; PMID: 17021819; http://dx.doi.org/10.1007/s00280-006-0343-1
43. Wang Y, Cabral F. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 2005; 1744:245-55; PMID:15950754; http://dx.doi.org/10.1016/j.bbamcr.2004.12.003
44. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003; 64:51-8; PMID:12815160; http://dx.doi.org/10.1124/mol.64.1. 51
45. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID: 19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026